Spot Biosystems has raised $40 Million in new Series A funding
According to filings with the U.S. Securities and Exchange Commission, Spot Biosystems has raised $40,000,000.00 in new Series A funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.
Investors in the company’s current round of funding include: Not Available.
About Spot Biosystems
Spot Biosystems is building the next generation of non-viral gene therapy with an extracellular vesicle (EV) delivery platform. Its foundational technology is designed to deliver genetic medicines that viral vectors cannot safely or effectively carry, capable of serial dosing, and avoids the challenges of viral immunogenicity and toxicity. Underpinned by its proprietary platform and proof of concept for safer and more effective therapeutics, the company is advancing a lead program for EV gene therapy that targets Duchenne muscular dystrophy and has raised $40 million in venture financing from leading investors.
To learn more, visit https://www.spotbiosystems.com/
Linkedin: https://www.linkedin.com/company/spotbiosystems/
Contact:
Andrew Lee, Co-Founder
https://www.linkedin.com/in/andrew-lee-md-phd-75937646/
SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.